Management

管理

• 批准号: 7575465
• 负责人: TIMOTHY A CROSS
• 金额: $ 8.28万
• 依托单位: FLORIDA STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-20 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7575465
• 关键词: Advisory Committees; Annual Reports; Charge; Code; Collaborations; Committee Members; Communication; Communication Tools; Consultations; Databases; Development; Discipline; Drug Delivery Systems; Engineering; Escherichia coli; Essential Genes; Financial Support; Florida; Frequencies; Funding Mechanisms; Goals; Grant; Image; Individual; Institutes; Institution; Laboratories; Membrane Proteins; Methods; Mutagenesis; Mutation; Mycobacterium tuberculosis; National Institute of Allergy and Infectious Disease; Participant; Pharmacologic Substance; Postdoctoral Fellow; Protein NMR Spectroscopy; Radio; Reporting; Research; Research Personnel; Research Project Grants; Screening procedure; Site; Technology; Universities; Work; assay development; base; design; drug development; experience; magnetic field; meetings; multidisciplinary; mycobacterial; novel; payment; programs; protein expression; protein structure; skills; solid state nuclear magnetic resonance; symposium; tuberculosis drugs; web site

The PI will have overall and final responsibility for the scientific management of the Program and will act in consultation with the Project Leaders (PLs) and Core Leaders (CLs) who will form an Executive Committee. The PI has considerable experience in the management of large research and user facility programs, as well as the management of a previous P01 grant. Florida State University, as the primary applicant institution will have the responsibility for establishing and maintaining the appropriate administrative and financial oversight. Corresponding administrative and financial support exists at each of the collaborating institutions. Team institutions will receive subcontracts from Florida State University. Subcontract payments will be approved by the PI following review of an annual work plan submitted by the investigators with the Core or Project leaders approval. Subcontracts will be reviewed annually at one of the biannual face-to-face meetings of the Team and Executive Committee (composed of Project and Core Leaders). The PI will have the responsibility following such consultation and additional discussion with External Advisory Committee members to discuss with the appropriate Program officer at NIAID any adjustment in the amount of the various subcontracts to maximize the Program's progress towards its aims. In addition to the face-to-face meeting the Executive committee will meet every month by conference call (video with powerpoint when beneficial), The Project and Core Leaders will also meet regularly by conference call with their individual project and core teams and minutes will be submitted to the PI. The Program will also establish an External Advisory Committee that will have diverse expertise in the TB and drug development arenas. In choosing committee members it will be our intent to expand the base of expertise, especially in the direction of potential drug development, so that we can charge the committee to assess our progress towards the goal of characterizing potential drug targets. We expect each member of the committee to meet annually with the Program in one of our face-to-face meetings. Since there are two of these we hope to have several committee members at each meeting. They will be asked to submit a brief report to the PI following each meeting. These reports will be part of the Annual Report to NIAID. The PI has full responsibility for reporting to NIAID on scientific progress and goals. The PLs and CLs have the responsibility to submit an annual report to the PI two weeks before the NIAID due date and following the second annual Program meeting. Florida State University has responsibility for reporting annually on the financial status of the Program

PI将对该计划的科学管理承担总体而最终的责任，并将采取行动 与项目负责人（PLS）和核心领导者（CLS）协商，他们将组成高管 委员会。 PI在大型研究和用户设施的管理方面具有丰富的经验 程序以及以前的P01赠款的管理。佛罗里达州立大学，作为小学 申请人机构将负责建立和维护适当的行政 和财务监督。每个合作中都存在相应的行政和财务支持 机构。 团队机构将从佛罗里达州立大学获得分包合同。分包付款将是 在审查调查人员核心提交的年度工作计划后，PI批准了 项目领导者批准。分包合同将在每年一次的一年面对面进行每年审查 团队和执行委员会的会议（由项目和核心领导人组成）。 PI将有 此类咨询和与外部咨询委员会的其他讨论之后的责任 成员在NIAID上与适当的计划官员进行讨论 各种分包合同以最大化该计划的进度朝着其目标。除了面对面 会议会议执行委员会将每月通过电话会议开会（与PowerPoint的视频 有益的），项目和核心领导者还将通过电话会议定期开会 项目和核心团队以及会议记录将提交给PI。 该计划还将建立一个外部咨询委员会，该委员会将在结核病领域具有多样化的专业知识 和药物开发领域。在选择委员会成员时，我们的意图是扩大 专业知识，尤其是在潜在药物开发的方向上，以便我们可以向委员会收取 评估我们朝着表征潜在药物靶标的目标的进展。我们希望每个成员的成员 委员会每年在我们的一次面对面会议中与该计划会面。由于有两个 我们希望每次会议都有几个委员会成员。他们将被要求提交简报 每次会议之后向PI报告。这些报告将成为NIAID年度报告的一部分。 PI对向NIAID报告科学进步和目标负有全部责任。 PLS和CLS 有责任在NIAID到期日之前两周向PI提交年度报告，并且 在第二届年度计划会议之后。佛罗里达州立大学有责任报告 每年有关该计划的财务状况